Boxer Capital
Latest statistics and disclosures from Boxer Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, TYRA, NUVL, BGNE, CYTK, and represent 33.54% of Boxer Capital's stock portfolio.
- Added to shares of these 10 stocks: TIL (+$24M), KYMR (+$21M), NRIX (+$13M), QURE (+$11M), APGE (+$11M), TERN (+$6.3M), SRRK (+$6.0M), SMMT (+$5.5M), CGEM, Bicara Therapeutics.
- Started 12 new stock positions in NRIX, SRRK, KYMR, TIL, MRSN, APGE, ZURA, Bicara Therapeutics, QURE, TERN. SMMT, DBVT.
- Reduced shares in these 10 stocks: FATE (-$11M), ALLO (-$9.0M), NKTX (-$7.1M), PSTX (-$7.1M), AMLX, ABSI, PRLD, IPSC, Atara Biotherapeutics, Dbv Technologies S A.
- Sold out of its positions in ABSI, ALLO, AMLX, Atara Biotherapeutics, Dbv Technologies S A.
- Boxer Capital was a net buyer of stock by $65M.
- Boxer Capital has $2.0B in assets under management (AUM), dropping by 7.31%.
- Central Index Key (CIK): 0001465837
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Boxer Capital
Boxer Capital holds 68 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 9.5 | $194M | 4.3M | 45.35 |
|
|
| Tyra Biosciences (TYRA) | 7.4 | $152M | 6.4M | 23.51 |
|
|
| Nuvalent Inc-a (NUVL) | 5.6 | $115M | 1.1M | 102.30 |
|
|
| BeiGene Sponsored Adr (BGNE) | 5.5 | $112M | 500k | 224.51 |
|
|
| Cytokinetics Com New (CYTK) | 5.4 | $111M | 2.1M | 52.80 |
|
|
| Springworks Therapeutics (SWTX) | 5.4 | $110M | 3.4M | 32.04 |
|
|
| Merus N V (MRUS) | 4.7 | $95M | 1.9M | 49.96 |
|
|
| Sarepta Therapeutics (SRPT) | 4.0 | $81M | 650k | 124.89 |
|
|
| Avidity Biosciences Ord (RNA) | 3.9 | $79M | 1.7M | 45.93 |
|
|
| Ideaya Biosciences (IDYA) | 3.4 | $70M | 2.2M | 31.68 |
|
|
| Tango Therapeutics (TNGX) | 3.1 | $63M | 8.2M | 7.70 |
|
|
| Argenx SE Sponsored Adr (ARGX) | 2.7 | $54M | 100k | 542.08 |
|
|
| Apellis Pharmaceuticals (APLS) | 2.4 | $50M | 1.7M | 28.84 |
|
|
| Akero Therapeutics (AKRO) | 2.4 | $48M | 1.7M | 28.69 |
|
|
| Anaptysbio Inc Common (ANAB) | 2.1 | $44M | 1.3M | 33.50 |
|
|
| Axsome Therapeutics (AXSM) | 1.8 | $36M | 400k | 89.87 |
|
|
| Iteos Therapeutics (ITOS) | 1.5 | $30M | 2.9M | 10.21 |
|
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.4 | $29M | 600k | 48.73 |
|
|
| Geron Corporation (GERN) | 1.3 | $27M | 6.0M | 4.54 |
|
|
| Third Harmonic Bio (THRD) | 1.3 | $27M | 2.0M | 13.55 |
|
|
| Rocket Pharmaceuticals (RCKT) | 1.3 | $27M | 1.5M | 18.47 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 1.2 | $25M | 1.6M | 15.29 |
|
|
| Instil Bio Com New (TIL) | 1.2 | $24M | NEW | 356k | 67.32 |
|
| Xenon Pharmaceuticals (XENE) | 1.2 | $24M | 600k | 39.37 |
|
|
| Immunovant (IMVT) | 1.2 | $24M | 825k | 28.51 |
|
|
| Kymera Therapeutics (KYMR) | 1.0 | $21M | NEW | 450k | 47.33 |
|
| Spyre Therapeutics Com New (SYRE) | 1.0 | $21M | 697k | 29.41 |
|
|
| Kura Oncology (KURA) | 1.0 | $20M | 1.0M | 19.54 |
|
|
| Kalvista Pharmaceuticals (KALV) | 0.9 | $18M | 1.6M | 11.58 |
|
|
| Nkarta (NKTX) | 0.9 | $18M | -28% | 4.0M | 4.52 |
|
| Oric Pharmaceuticals (ORIC) | 0.9 | $18M | 1.7M | 10.25 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.9 | $18M | 400k | 43.89 |
|
|
| Fate Therapeutics (FATE) | 0.9 | $17M | -39% | 5.0M | 3.50 |
|
| Enliven Therapeutics (ELVN) | 0.8 | $17M | 671k | 25.54 |
|
|
| Replimune Group (REPL) | 0.8 | $17M | 1.5M | 10.96 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 0.8 | $17M | 1.2M | 13.93 |
|
|
| Cullinan Oncology (CGEM) | 0.7 | $15M | +37% | 908k | 16.74 |
|
| Arvinas Ord (ARVN) | 0.7 | $15M | 609k | 24.63 |
|
|
| Eliem Therapeutics (ELYM) | 0.7 | $13M | 2.6M | 5.09 |
|
|
| Relay Therapeutics (RLAY) | 0.6 | $13M | 1.8M | 7.08 |
|
|
| Nurix Therapeutics (NRIX) | 0.6 | $13M | NEW | 563k | 22.47 |
|
| Prothena Corp SHS (PRTA) | 0.6 | $12M | 690k | 16.73 |
|
|
| Uniqure NV SHS (QURE) | 0.5 | $11M | NEW | 2.2M | 4.93 |
|
| Apogee Therapeutics (APGE) | 0.5 | $11M | NEW | 179k | 58.74 |
|
| Olema Pharmaceuticals (OLMA) | 0.4 | $7.8M | 650k | 11.94 |
|
|
| Iovance Biotherapeutics (IOVA) | 0.3 | $7.0M | 750k | 9.39 |
|
|
| Century Therapeutics (IPSC) | 0.3 | $6.7M | -20% | 3.9M | 1.71 |
|
| Jasper Therapeutics Com New (JSPR) | 0.3 | $6.6M | 350k | 18.81 |
|
|
| Sana Biotechnology (SANA) | 0.3 | $6.4M | 1.5M | 4.16 |
|
|
| Terns Pharmaceuticals (TERN) | 0.3 | $6.3M | NEW | 752k | 8.34 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.3 | $6.0M | NEW | 750k | 8.01 |
|
| Poseida Therapeutics I (PSTX) | 0.3 | $5.7M | -55% | 2.0M | 2.86 |
|
| Summit Therapeutics (SMMT) | 0.3 | $5.5M | NEW | 250k | 21.90 |
|
| Engene Holdings (ENGN) | 0.2 | $4.8M | 728k | 6.60 |
|
|
| Prelude Therapeutics (PRLD) | 0.2 | $3.5M | -33% | 1.7M | 2.07 |
|
| Bicara Therapeutics | 0.2 | $3.4M | NEW | 135k | 25.47 |
|
| Mersana Therapeutics (MRSN) | 0.2 | $3.4M | NEW | 1.8M | 1.89 |
|
| Boundless Bio (BOLD) | 0.1 | $2.5M | 711k | 3.47 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.1 | $2.2M | 506k | 4.35 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $1.7M | 450k | 3.68 |
|
|
| Protara Therapeutics Com Stk (TARA) | 0.1 | $1.5M | 812k | 1.83 |
|
|
| Health Sciences Acq Corp 2 (OBIO) | 0.1 | $1.2M | 238k | 5.14 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.1 | $1.2M | NEW | 300k | 4.06 |
|
| Bioatla (BCAB) | 0.1 | $1.2M | 686k | 1.76 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.0 | $470k | 309k | 1.52 |
|
|
| DBV Technologies S A Sponsored Adr (DBVT) | 0.0 | $175k | NEW | 250k | 0.70 |
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $26k | 267k | 0.10 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.3k | 67k | 0.02 |
|
Past Filings by Boxer Capital
SEC 13F filings are viewable for Boxer Capital going back to 2015
- Boxer Capital 2024 Q3 filed Nov. 14, 2024
- Boxer Capital 2024 Q2 filed Aug. 14, 2024
- Boxer Capital 2024 Q1 filed May 15, 2024
- Boxer Capital 2023 Q4 filed Feb. 14, 2024
- Boxer Capital 2023 Q3 filed Nov. 14, 2023
- Boxer Capital 2023 Q2 filed Aug. 14, 2023
- Boxer Capital 2023 Q1 filed May 15, 2023
- Boxer Capital 2022 Q4 filed Feb. 14, 2023
- Boxer Capital 2022 Q3 filed Nov. 14, 2022
- Boxer Capital 2022 Q2 filed Aug. 15, 2022
- Boxer Capital 2022 Q1 filed May 16, 2022
- Boxer Capital 2021 Q4 filed Feb. 14, 2022
- Boxer Capital 2021 Q3 filed Nov. 15, 2021
- Boxer Capital 2021 Q2 filed Aug. 16, 2021
- Boxer Capital 2021 Q1 filed May 17, 2021
- Boxer Capital 2020 Q4 filed Feb. 16, 2021